TY - JOUR T1 - High sensitivity CDC EUA SARS-CoV-2 kit-based End Point-PCR assay JF - medRxiv DO - 10.1101/2020.05.11.20098590 SP - 2020.05.11.20098590 AU - Byron Freire-Paspuel AU - Patricio Vega-MariƱo AU - Alberto Velez AU - Marilyn Cruz AU - Miguel Angel Garcia-Bereguiain Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/18/2020.05.11.20098590.abstract N2 - SARS-CoV-2 diagnosis is based on RT-qPCR protocols that limited testing to facilities with Real Time PCR devices and probes supply. Here we described and adapted version of the RT-qPCR CDC protocol where N1, N2 and N3 primers are used for end point PCR and amplicons are visualized on agarose gel with a limit of detection up to 20 viral RNA copies/uL. This protocol would allow to extend SARS-CoV-2 diagnosis to basic molecular biology laboratories with a great impact on surveillance programs at developing countries.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available upon request. ER -